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ABSTRACT:
Noncoding RNAs are key players in the maintenance of genomic integrity, 
particularly in silencing the expression of repetitive elements, some of which are 
retrotransposable and capable of causing genomic instability. Recent computational 
studies suggest an association between L1 expression and the generation of small 
RNAs. However, whether L1 expression has a role in the activation of small RNA 
expression has yet to be determined experimentally. Here we report a global analysis 
of small RNAs in deep sequencing from L1-active and L1-silenced breast cancer cells. 
We found that cells in which L1 expression was silenced exhibited greatly increased 
expression of a number of miRNAs and in particular, members of the let-7 family. 
In addition, we found differential expression of a few piRNAs that might potentially 
regulate gene expression. We also report the identification of several repeat RNAs 
against LTRs, LINEs and SINE elements. Although most of the repeat RNAs mapped 
to L1 elements, in general we found no significant differences in the expression levels 
of repeat RNAs in the presence or absence of L1 expression except for a few RNAs 
targeting subclasses of L1 elements. These differentially expressed small RNAs may 
function in human genome defence responses.
INTRODUCTION
Small RNAs have recently emerged as being 
important in the control of gene expression in almost all 
biological processes. Many different types of small RNA, 
including microRNAs (miRNAs), endogenous siRNAs 
(endo-siRNAs), small nucleolar RNAs (snoRNAs) 
and more recently, Piwi-interacting RNAs (piRNAs), 
are expressed in a variety of tissues and exert diverse 
effects on cellular functions [1-3]. The different classes 
of small RNAs are generally distinguished by their mode 
of biogenesis, protein partners and/or biological function 
[4]. miRNAs are generated from a single cleavage event 
of a short hairpin pre-miRNA by the Dicer enzyme, 
and are loaded onto Argonaute proteins and then guide 
translational repression of mRNAs. Some miRNAs can 
also promote degradation of mRNAs by deadenylation [5]. 
Endo-siRNAs are a class of small interfering RNA with 
sequences that are complementary to other endogenous 
mRNAs [6]. They are often generated from multiple 
Dicer cleavages of long precursor dsRNAs or generated 
from genomic sources that include the folding back of 
inverted repeats, sites of bidirectional transcription, and 
read-through antisense transcripts of retrotransposons and 
pseudogenes [7, 8]. Recent advances in high-throughput 
small RNA sequencing have resulted in the identification 
of a growing number of small RNAs in animals. These 
include many repeat-associated siRNAs (originally termed 
rasiRNAs), which are produced from retrotransposon-
derived dsRNAs in Drosophila germline cells. These 
repeat-associated siRNAs are now known as piRNAs [9], 
since they are bound by Piwi proteins and are produced 
by a Dicer-independent mechanism. piRNAs have been 
shown to play a critical role in silencing retrotransposons 
as well as having a role in the assembly of heterochromatin 
structures to silence gene expression [10, 11]. 
The human genome contains large numbers of 
repetitive sequences and retrotransposable elements 
both within and between genes. These repeat elements, 
accounting for nearly 45% of the genome, are grouped 
into four classes: LINEs (long interspersed elements), 
SINEs (short interspersed elements), LTRs (long 
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terminal repeats) and DNA transposons. The most active 
retrotransposons are the LINE-1 or L1 elements [12] 
which are capable of replicating through their own reverse 
transcriptase and endonuclease enzymes and inserting 
DNA copies at new genomic locations. This can often 
lead to deleterious effects in the genome, such as through 
the insertion of L1 DNA copies into protein-coding 
regions of genes, abolishing their function. They may also 
negatively affect genome integrity because of their ability 
to create dsDNA breaks during retrotransposition [13]. A 
recent study surveying human tumors and comparing their 
genomes to those of adjacent normal tissues suggested that 
tumors have high frequencies of L1 insertions and dsDNA 
breaks that are not present in normal tissues [14, 15]. The 
activation of L1 elements has also been implicated in the 
genomic insertions of ~8000 processed pseudogenes [16] 
and the retrotransposition of nonautonomous elements, 
such as retrogenes, Alu and SVA elements [17], which can 
affect genomic structure in a multitude of ways. Thus, to 
protect genome integrity, cells normally employ a number 
of defense strategies, with epigenetic mechanisms, such 
as silencing by small RNAs, DNA methylation, or histone 
modifications, playing key roles in keeping L1 elements 
in check.
Several studies carried out in somatic cells of 
Drosophila and in mouse oocytes have shown that endo-
siRNAs regulate retrotransposons and protein-coding 
genes that are complementary to the endo-siRNAs [6, 
18], similar to the function of piRNAs in germline cells 
[10]. Interestingly, recent evidence shows that piRNAs 
are also expressed in human cancer cells and their altered 
expression plays a role in the development of cancer 
[19]. In relation to this, we recently identified a subset of 
L1-specific siRNAs that are differentially expressed in 
a wide range of breast cancer cells compared to normal 
cells [20]. Overexpression of these siRNAs markedly 
silenced endogenous L1 expression through increased 
DNA methylation of the L1 promoter. These findings 
reveal a role for small RNAs in humans and indicate 
that depletion of L1-specific siRNAs is most likely to 
be one of the reasons for the activation of L1 elements 
in cancer cells. However, the expression status and roles 
of other small RNAs such as miRNAs and piRNAs have 
largely remained unknown. Several studies performed 
in human cancer cells have reported that blocking the 
retrotransposition of L1 elements not only controls L1 
activity but also alters the expression of many genes 
involved in the proliferation and differentiation of cancer 
cells [21]. This raises an important question of how the 
silencing of L1 activity contributes to the regulation of 
these genes. 
Nearly 25% of human promoters have been 
reported to contain retrotransposon-derived sequences 
including many cis-regulatory sequences [22], which 
are involved in specific patterns of gene expression. 
Interestingly, a significant number of miRNAs and other 
small RNAs are also derived from repetitive sequences 
[23, 24], which may in turn regulate the expression 
of other cellular genes harboring repetitive sequences 
in their transcripts.  Through computational searches, 
two recent studies identified a number of small RNAs, 
including miRNAs and snoRNAs [25, 26], which 
are derived from the retrotransposition activity of L1 
elements. Many of these small RNAs are surrounded by 
sequence features that are typical of L1 elements, such 
as target site duplications (TSDs) and poly-A tails at 
their 3’ ends. These analyses propose the involvement 
of L1 retrotransposition in generating large numbers of 
small RNAs in the human genome [27]. Moreover, these 
studies also suggest the existence of many tissue-specific 
retrotransposon-derived small RNAs that may be a driving 
force for creating new regulatory elements involved in 
the control of gene expression [25, 26]. Despite these 
extensive bioinformatic analyses, the existence of such 
a mechanism needs to be experimentally verified. In 
light of the accumulating data suggesting a connection 
between L1 elements and the generation of small RNAs, 
we investigated this relationship using high-throughput 
deep sequencing. To investigate whether the expression of 
L1 elements was correlated with small RNA expression, 
we analyzed the profile of small RNA expression with 
respect to the activation or silencing of L1 elements using 
a published L1-specific endogenous siRNA sequence 
that specifically silences L1 expression in human cells 
[20]. Here, we show that rather than generating small 
RNAs, L1 expression globally reduces the expression 
of small RNAs. Conversely, silencing of L1 expression 
up-regulates the expression of a number of miRNAs and 
piRNAs, sometimes very markedly. 
RESULTS
Generation of L1 silencing in breast cancer cells
To determine whether the expression of L1 elements 
in human cells plays a role in controlling the level of small 
RNA expression, we used a human T47D breast cancer 
cell line because our recent studies showed high levels 
of L1 retrotransposition and concomitantly low levels 
of L1-specific siRNAs in these cells [15, 20]. To silence 
L1 expression we used a published L1-specific siRNA 
sequence (endo453) [20], that can specifically silence 
endogenous L1 element expression by targeting the L1 
5’-UTR promoter region (at nucleotide positions 453 to 
475). In this assay, we stably transfected T47D cells with 
an shRNA construct (mimicking the L1-specific endo453 
sequence) whose expression was driven by constitutively 
expressing the U6 promoter. A scrambled endo-siRNA 
sequence with no homology to any known genes was 
used as a control (Figure 1A). As assessed by qRT-PCR 
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Figure 2: Expression of miRNAs. (a) Length distribution of small RNAs in L1- active and L1-silenced cells. (b) Scatter plot showing 
normalized read counts for miRNAs in L1-silenced cells versus L1-active. Blue symbols denote miRNAs. (c) Bland-Altman plot of 
normalized read counts for miRNAs in L1-silenced library versus L1-active.  The difference in the read counts (L1-silenced – L1-active) 
(vertical axis) is plotted against the average of the read counts [(L1-silenced + L1-active)/2]. If the read count for a particular miRNA 
species is identical in both libraries, the point is located on the middle horizontal line. The other horizontal lines represent the ± 2SD 
thresholds for the data. Points lying further away from the middle horizontal line are more likely to be significantly differentially expressed. 
(d) Higher magnification view of left-hand side of Figure 2c.
Figure 1: Endo453 sequence controls L1 expression. (A) Sequences of L1-specific endo453 and scrambled control siRNAs are 
shown. (B) Quantitative RT-PCR analysis of L1 ORF1 and ORF2 mRNAs after stable transfection with endo453 and scrambled control 
siRNAs. Each bar represents the relative expression changes between L1-active (scrambled) and L1-silenced (endo453) cells after being 
normalized to HPRT1 as an internal control. Fold change was calculated from 2-∆∆CT and p values by an unpaired t test. Error bars show 
s.d. (n=4). (C) Western blot of L1 protein in T47D cells stably transfected with endo453 and scrambled siRNAs. α-tubulin was used as a 
loading control. The whole cell extracts from NTera.2D1 and parental T47D cells were performed in parallel. 
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Table 1: Distribution of small RNAs in L1-active and L1-silenced libraries.
a) Alignment against microRNAs (output from alignment with the miRanalyzer pipeline)















































3.10% 4.10% 0.08% 0.12% 0.18% 0.22% 0.00% 0.00% 0.36% 0.54% 0.08% 0.10%
Read 




18.30% 35.50% 0.08% 0.13% 0.16% 0.18% 0.00% 0.00% 0.24% 0.71% 0.16% 0.17%
afraction of known miRNAs:  % of known microRNAs detected in the sample/total number of known microRNAs in miRBase
bfraction of unique reads:  the fraction of unique reads in the library that mapped to miRBase
cread count:  the total count of all reads mapped to mirBase (i.e. the sum over all unique reads in the library of the number of times each unique read appears)
dfraction of total read count:  read count in c. above as a percentage of the total number of reads in the library (21,266,358 for L1-active and 22,745,765 for 
L1-silenced as described in Results)
b) Alignment against Piwi-interacting RNAs  (output from alignment against human piRNABase)
hsa_piRNAs
L1-active L1-silenced
Number of known piRNAs detected 314 340
Fraction of known piRNAs detected 1.34% 1.45%
Read count 77732 70869
c) Alignment against repeat RNAs (output from alignment against deepBase human rasRNA)
 Antisense Sense Ratio of antisense/sense
 L1-active L1-silenced L1-active L1-silenced L1-active L1-silenced
LINE 141597 103436 137990 83348 1.02 1.24
SINE 26351 36022 34337 33628 0.7 1.07
LTR 47552 43448 34073 24638 1.39 1.76
DNA_transposon 15165 15052 4050 4614 3.74 3.26
Satellite DNA 428 388 104 117 4.11 3.31
Small cytoplasmic RNA 0 0 9045 30041
Unknown class/family 4866 6299 220374 307964 0.02 0.02
Unknown genomic repeat 309 233 104 117 2.97 1.99
rRNA 64 22 61071 75260 0.001 0.0002
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analysis, we achieved L1 silencing efficiencies of 72 ± 
4.6% (p=0.001) and 78 ± 5.8% (p=0.003) for ORF1 and 
ORF2 mRNA, respectively (Figure 1B). The effectiveness 
of the endo453 sequence was further confirmed by 
western blotting of whole-cell lysates from the endo453, 
scrambled or parental cells using anti-ORF1 antibodies 
(Figure 1C). Human embryonic carcinoma NTera.2D1 
cells, which express high levels of L1 protein, served as 
a control. The resulting assays confirmed that the relative 
expression of L1 mRNA and protein was significantly 
reduced in endo453 cells compared with scrambled or 
the parental T47D cells. Together, these results show that 
the endogenous expression of human L1 elements can 
be efficiently silenced by an artificially transfected L1-
specific siRNA sequence. 
Deep sequencing of small RNAs
To investigate whether the activation or silencing of 
L1 elements plays any role in contributing to small RNA 
expression, we used the Illumina GAIIx high-throughput 
sequencing platform to sequence small RNA libraries from 
the endo453 (L1-silenced) and scrambled (L1-active) cells. 
Since L1 expression was controlled by the introduction of 
exogenous (synthetic) endo453, the introduced sequences 
were bioinformatically removed from the files of Illumina 
reads prior to mapping in order to identify unbiased 
expression of small RNAs in the L1 silenced library. We 
then used the miRanalyzer small RNA mapping pipeline 
[28] to map the reads to miRBase and to identify and 
annotate all species of miRNAs present in the libraries 
[29]. In order to identify expressed piRNA sequences, we 
aligned the reads to the piRNABank database (human.tar.
gz) [30] using CLC Genomics Workbench (version 5.5.1) 
(http://www.cicbio.com). Finally, we mapped the reads 
to the deepBase repeat-associated small RNA database 
(Human_sense_rasRNA_deepBase.fasta, Human_
antisense_rasRNA_deepBase.fasta) [31] to detect repeat-
associated RNA also using CLC Genomics Workbench. 
An overview of the sequencing and mapping results for 
the two libraries is given in Table 1. 
The distribution of lengths of the L1-silenced small 
RNAs was similar to that of the L1-active library, with 
peaks at 22–23-nt (Figure 2A). After removal of singleton 
reads and reads of less than 17-nt from each library by 
the miRanalyzer pipeline, there were 21,266,358 and 
22,745,765 reads in the L1-active and L1-silenced 
libraries, respectively. Surprisingly however, 8,076,212 
sequence reads from the L1-silenced sample mapped to 
known mature miRNAs compared to 3,882,279 in the 
L1-active sample. This large increase in numbers of reads 
mapping to known miRNAs in the L1-silenced library 
was unexpected. However, we found that a small number 
of very highly differentially expressed miRNAs were 
responsible for most of the discrepancy (Figure 2C). In 
particular, in the intermediate miRanalyzer file of mapped 
reads at the step prior to normalization (by default named 
as microRNA.diffexpr in the miRanalyzer pipeline), 
1,855,633 reads mapped to let-7a in the L1-silenced 
library compared to 149,428 reads in the L1-active library, 
accounting for ~41% of the difference in the unnormalized 
counts of the mapped sequence reads. This large difference 
remained even after normalizing the read counts in both 
libraries using the DESeq package which is incorporated 
into the standard miRanalyzer pipeline [32]. DESeq uses 
a median-based scaling method to normalize read counts 
rather than scaling based on the total read counts in each 
library. The key steps are as follows: first a reference 
sample is constructed by calculating the geometric mean 
Figure 3:Expression of piRNAs. (a) Scatter plot showing normalized read counts for piRNAs in L1-silenced cells versus L1-active. 
Blue symbols denote piRNAs. (b) Bland-Altman plot of normalized read counts for piRNAs in L1-silenced cells versus L1-active. 
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over all samples of the counts for each mapped miRNA 
species. Next, for each sample, the quotient of the mapped 
read count of each miRNA species to that in the reference 
sample is calculated. The quotients for each sample 
are sorted in numerical order and the median quotient 
becomes the scaling factor for the sample. This is a robust 
method of normalizing read counts when a relatively few 
highly differentially expressed small RNA species might 
bias the normalization of the library sizes if a global 
scaling method based on total read counts in each library 
was used [32, 33]. 
Differentially expressed miRNAs
To identify miRNAs that were differentially 
expressed between active and L1-silenced cells, we 
mapped the reads from both libraries against miRBase 
(version 16) using the miRanalyzer pipeline [29], 
which also includes normalization and calculation of 
fold changes in the R/Bioconductor DESeq software 
package (version 1.6.0) [32]. To determine the rankings 
of differentially expressed miRNAs, we used the GFOLD 
(generalized fold change) algorithm (version 1.0.7) [34]. 
The GFOLD algorithm takes into account the observation 
that the fold changes of expressed species with low read 
counts are less reliable than those of species with high read 
counts and estimates a fold change value for each species 
based on the posterior distribution of the raw fold change. 
The analysis revealed numerous differentially expressed 
and highly expressing miRNAs in the L1-silenced versus 
the L1-active cells (Supplementary Table S1).  Overall, 23 
miRNAs were up-regulated in the L1-silenced cells based 
Figure 4:Expression of sense and antisense repeat-associated small RNAs. (a) Bland-Altman plot of normalized read counts 
(mapped to individual genomic loci) for sense repeat RNAs in L1-silenced cells versus L1-active. (b) Higher magnification view of left-
hand side of Fig4a. (c) Bland-Altman plot of normalized read counts (mapped to individual genomic loci) for antisense repeat RNAs in 
L1-silenced cells versus L1-active. (d) Higher magnification view of left-hand side of Fig4c. Blue symbols represent repeat-associated 
small RNAs.
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on a GFOLD (0.01) threshold of 2. The most abundantly 
expressed miRNAs were the let-7 family members; let-
7a, let-7b, let-7c, let-7e and let-7f were all up-regulated 
in the L1-silenced cells, in some cases, very markedly 
(Figure 2C). This result is consistent with published 
miRNA-profiling studies in many human cancer cells in 
which down-regulation of let-7 family members has been 
reported more commonly than their up-regulation [35]. 
In addition to the let-7 family members, large changes 
were also seen in the expression of miR-196a, miR-30d, 
miR-103, miR-425, miR-191 and miR-200c (Figure 
2D). Although these miRNAs were expressed at high 
levels in both libraries, the differences in their expression 
between the two libraries helped to account for most of the 
difference in the total number of mapped reads between 
the two libraries. 
The canonical miRNA biogenesis pathway 
generates an miRNA duplex that consists of an miRNA 
and miRNA* strand. Several miRNA* species have been 
recently found in humans and some of them have been 
Figure 5: Mapping of sense and antisense reads to RepeatMasker families. (a) Barplot showing accumulated normalized 
read counts of sense repeat-associated small RNAs after mapping L1-active and L1-silenced libraries against human deepBase sense 
rasRNA. The mapped reads were annotated with their RepeatMasker name and grouped into their RepeatMasker families. The totals of the 
normalized read counts belonging to each class are shown. Colour bars: L1-active sense reads, yellow: L1-silenced sense reads, blue. (b) 
Barplot showing a breakdown of the sense reads in the “Unknown” group. Only reads with a total accumulated count of greater than 10 
in both libraries and a fold change greater than 2 are shown. Colour bars: L1-active sense reads, yellow: L1-silenced sense reads, blue. (c) 
Barplot showing accumulated normalized read counts of antisense repeat-associated small RNAs after mapping L1-active and L1-silenced 
libraries against human deepBase antisense rasRNA. (d) Barplot showing a breakdown of the antisense reads in the “Unknown” group.
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implicated in differentiation of cancer cell states [36].  In 
the current study, we identified three typical miRNA* 
species (miR-149*, miR-625* and miR-9*) that were 
exclusively expressed in the L1- silenced cells with 
normalized read counts ≥ 10 (Supplementary Table S1). 
In addition, we found three miRNA*s (miR-664*, miR-
505* and miR-32*) that were differentially expressed 
between the two cell types with at least a 5x fold change. 
Several studies have described miRNA biogenesis by 
an alternative miRNA-processing pathway that uses the 
intron-splicing machinery instead of the Drosha/Dgcr8 
endonuclease to generate miRNA precursors (called 
miRtrons) from intronic sequences [37]. One of the most 
highly differentially expressed was miR-664, a typical 
miRtron whose miRNA-664 (4 vs. 31) and miR-664* 
(25 vs. 346) sequences flank the edges of its host intron 
in a pattern reminiscent of miRtron miRNA precursors. 
The host gene of the miR-664 intron has been identified 
as RAB3GAP1, and the sequence of miR-664 overlaps 
with an annotated snoRNA, ACA38B [27]. PhastCons 
scores, which reflect probabilities of selective maintenance 
through evolution, extend to the edges of the miRNA 
hairpin (data not shown), suggesting that the miR-664 
locus is highly conserved in the human, chimpanzee and 
mouse lineages. Moreover, we also found a number of 
newly identified miRNAs that were expressed only in the 
L1-silenced cells although at low levels, including miR-
3662, miR-3174, miR-3146, miR-3192 and miR-3605-5p 
(Supplementary Table S1). 
Differential expression of piRNAs
piRNAs are a distinct class of small RNAs that 
interact with Piwi proteins and are involved in epigenetic 
and post-transcriptional silencing of retrotransposons and 
other genomic repeats in germline cells. Unlike miRNAs, 
which are in the size range of 21-23 nt, piRNAs are 24-31 
nt in length. piRNA sequences do not have a precursor 
with a stem-loop and are not processed by Dicer. While 
there have been few reports of the presence of Piwi 
proteins in human cancers [38], one recent study did 
confirm the expression of piRNAs in human gastric cancer 
cells [39]. To identify differentially expressed piRNAs and 
other small RNAs in addition to miRNAs, we selected the 
adapter-trimmed reads in each library with lengths greater 
than 23-nt using the filter function in CLC Genomics 
Workbench  and mapped this subset of reads from each 
library against the human piRNABank database [30]. After 
normalization of the reads with DESeq, a total of 77,732 
reads in the L1-active and 70,869 reads in the L1-silenced 
cells matched 314 and 340 piRNA sequences, respectively, 
after deleting reads with a normalized mapped read count 
of 1 (Table 1). We found that the expression levels of 
most piRNAs were relatively constant in the L1-active 
and silenced libraries. However, we found a number of 
differentially expressed piRNAs in the L1-silenced versus 
the L1-active cells (Figure 3A).  Overall, 22 and 26 
piRNAs were up- and down-regulated, respectively in the 
L1-silenced cells based on the GFOLD thresholds of 2.0 
Figure 6: Summary of mapped small RNAs for L1-active and L1-silenced libraries. (a) Barplot showing an overview of 
the accumulated normalized read counts after mapping L1-active and L1-silenced libraries against miRBase, human deepBase sense and 
antisense rasRNA.fasta and the human piRNABank database. Colour bars: For reads mapped to miRBase and piRNABank: L1-active reads, 
yellow; L1-silenced reads, blue. For reads mapped to deepBase: L1-active sense reads, yellow; L1-silenced sense reads, blue; L1-active 
antisense reads, red; L1-silenced antisense reads, green. (b) Higher magnification view of Fig6a after omitting reads mapped to miRBase.
Oncotarget4111www.impactjournals.com/oncotarget
and -0.5 respectively (Supplementary Table S2). 
The most highly differentially expressed piRNAs as 
assessed by GFOLD were hsa_piR_000586 (fold change 
= 22x), hsa_piR_001101 (14x) and hsa_piR_020450 
(16x) which were all up-regulated in the L1-silenced cells 
(Figure 3B).  The extent of down-regulation of piRNA 
expression in the L1-silenced cells was not as marked 
as that of up-regulation. For instance, the most down-
regulated piRNA in the L1-silenced cells as assessed by 
GFOLD was hsa_piR_020582 (fold change = -10.35x). 
Intriguingly, an NCBI BLAST search with the hsa_
piR_000586 DNA sequence (28-nt) showed a match 
with 100% identity to a C/D box snoRNA residing in an 
intronic region of the Mortalin/GRP75 gene, an oncogene 
that is overexpressed in human cancers [40]. The E-value 
was 8x10-7. BLAST searches with the sequences of hsa_
piR_001101 and hsa_piR_020450 also gave hits to C/D 
box snoRNAs residing in the introns of genes. These 
observations suggest that such piRNAs may have a role 
influencing gene expression. Although the functions of 
piRNAs are quite diverse and largely unknown, some of 
the differentially expressed piRNAs observed here may 
be involved in regulating cell activities and further studies 
in this area should reveal the functions of these piRNAs. 
Differential expression of repetitive RNA 
Repeat-associated RNA refers to a class of 
noncoding small RNAs that includes transcripts from 
genomic repeats. Although it is unclear how they are 
processed and their biological functions are largely 
unknown, repeat-associated small RNAs map to repetitive 
elements such as LINEs, SINEs and LTRs. Like siRNAs, 
most repeat-associated small RNA sequences are in the 
size range of 18-23-nt. Until recently, all repeat-associated 
small RNAs were grouped together based on their genomic 
locations as rasRNAs [31]. While a number of earlier 
studies dismissed repeat-associated small RNA expression 
as genomic noise, one recent study identified functions for 
repeat RNA in the cell cycle and in DNA repair [41]. To 
identify differentially expressed repeat-associated small 
RNAs in addition to miRNAs and piRNAs, we mapped 
subsets of the small RNA libraries (i.e. reads < 24 nt in 
length from both the L1-active and L1-silenced libraries) 
against the human deepBase database [31]. The deepBase 
database contains human repeat RNAs that map to known 
repeat elements as well as large numbers of reads mapped 
to unique loci in the human genome. Reads were mapped 
against the human rasRNA antisense and sense fasta files 
downloaded from deepBase (Human_antisense_ rasRNA_
deepBase.fasta and Human_ sense_rasRNA_deepBase.
fasta as of July 2011). As with mapping against miRBase 
and piRNABank, the mapped read counts of each class of 
repeat RNA were normalized using the R/Bioconductor 
DESeq package [32]. The mapping procedure identified 
high levels of expression from many distinct repeat loci 
in both libraries. We analyzed the reads mapping to 
repeat RNA by first considering reads mapping to specific 
genomic loci, followed by grouping reads based on their 
repeat family and class. 
Using Unix command-line tools and Perl and 
R scripts (available on request), we extracted the 
RepeatMasker [42] annotation of each mapped deepBase 
read (contained in the header of each read in the 
deepBase fasta files) and grouped the mapped reads by 
RepeatMasker class/family name. Read counts belonging 
to each class and family were summed up with R scripts 
to obtain the total reads belonging to each class and family 
of repeat element. After grouping reads into their repeat 
class (LINE, SINE etc), we found that for the LINE 
class, sense and antisense expression were very similar in 
the L1-active cells (ratio: 1.02, Table 1c), while in L1-
silenced cells, LINE antisense expression was 24% of 
that of sense expression. At present, the relevance of this 
discrepancy is unclear but it is likely to be a result of L1 
silencing. At the level of individual genomic loci (i.e., 
after annotating reads with their deepBase accession), we 
found differentially expressed sense and antisense loci. 
The Bland-Altman plots (Figure 4A-B) show that the 
sense loci most likely to be significantly down-regulated 
in the L1-silenced cells are hgur000839476 (belonging to 
the L1PB4 family) and hgur000013038 (belonging to the 
L1M7 family). There were also numerous differentially 
expressed loci with low levels of expression including 
repeats from the L1M7, L1MC5, L1MEd, L1MC1, 
LTR33 and ERVL-B4-int families (Figure 4A-B). For 
reads mapping to individual antisense loci, the loci most 
likely to be significantly down-regulated in the L1-
silenced cells include hgur000890658, hgur000013075 
and hgur000890657 (all belonging to L1M5) while 
hgur000142641 and hgur000142640 (belonging to MIRc) 
are up-regulated in L1-silenced cells (Figure 4C-D).
The number of sense and antisense reads in each 
repeat RNA family and their relative fold changes 
between the two libraries are summarized in Figure 5A-
D. In some cases, there was no RepeatMasker name for 
a particular deepBase entry and these reads are listed in 
the “Unknown” category and breakdowns of these are 
shown in Figures 5B and 5D. When grouped according 
to their RepeatMasker family, a large majority of the 
sense and antisense reads mapped to either L1 elements 
or an “Unknown” family lacking a RepeatMasker family 
annotation. For the sense reads, mapping to the L1 family 
and the “Unknown” category (comprising mainly 5S 
RNA, small cytoplasmic RNA (scRNA), and LSU-rRNA_
Hsa) dominates the other families. Notably, 131,177 reads 
in the L1-active and 76,825 reads in the L1-silenced 
libraries mapped to active L1 elements compared to 1103 
and 1345 reads, respectively, against the inactive LINE L2 
family (Figure 5A). The high proportion of repeat RNAs 
expressed against L1 elements is not unexpected as L1 
is the only known active retrotransposon in the human 
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genome and, as expected, L1 expression was markedly 
repressed in the L1-silenced cells. The most interesting 
finding for the “Unknown” group of the sense reads is the 
marked increase in reads mapping to the HY1, HY3, HY4 
and HY5 categories of scRNA in the L1-silenced cells 
(with fold changes ranging from 2.6x to 4.0 x), and the 
marked increase in reads mapping to tRNA and the U3, U8 
and U17 snoRNA (small nucleolar RNA) species (Figure 
5B). A similar pattern was also seen for the antisense reads 
except that the “Unknown” group was much smaller. 
There was an increase in the numbers of antisense reads 
mapping to L2 elements (but still < 10% of the values for 
L1) and MIR elements in the L1-silenced cells  (Figure 
5C). The up-regulation of scRNA and snoRNA expression 
in the L1-silenced cells is consistent with a generalized up-
regulation of rRNA biogenesis and protein synthesis as the 
L1-silenced cells assume a more differentiated phenotype.
A summary of the small RNA mapping results 
for the L1 active and L1-silenced libraries is given in 
Figure 6A-B.  As shown in Figure 6A, the expression of 
piRNAs and repeat-associated small RNA families is at 
a relatively low level compared to miRNA expression. 
In mammals, repeat-associated small RNAs have not yet 
been investigated thoroughly. However, some of the endo-
siRNAs that are known to originate from retrotransposons 
in germline cells have also been shown to be expressed 
in somatic cells of Drosophila and their biogenesis is at 
least in part, Dicer-dependent [43]. Thus it is plausible that 
some human repeat-associated small RNAs might exist 
as remnant copies from germline and embryo cells. At 
present it remains unclear whether they act as functional 
siRNAs in controlling repetitive elements in humans, 
similar to the action of Drosophila endo-siRNAs in 
somatic cells [6]. Because our knowledge of the functional 
and mechanistic roles of repeat-associated small RNAs is 
at an early stage, further studies focusing on the regulatory 
mechanisms of repeat RNA expression will shed light on 
these questions. Nonetheless, our studies have identified 
that in addition to miRNAs and piRNAs, repeat RNAs 
are indeed expressed in breast cancer cells and some of 
the repeat RNAs identified could potentially regulate the 
expression of LINEs and other retrotransposons in the 
human genome. 
DISCUSSION
In light of the accumulating data reporting a 
connection between the expression of L1 elements and 
the generation of retrotransposon-derived small RNAs, we 
analyzed changes in the expression profile of miRNAs, 
piRNAs and repeat-associated small RNAs before and after 
silencing the expression of L1 elements in breast cancer 
cells, using the published L1-specific endo453 sequence 
that specifically silences endogenous L1 expression [20]. 
We found that rather than generating small RNAs, L1 
expression globally reduces the expression of small RNAs. 
The principal finding was of greatly increased expression 
of members of the let-7 family of miRNAs, and increased 
expression (above a GFOLD threshold of 2.0) of several 
other miRNAs including hsa-miR-196a, hsa-miR-30a/d, 
hsa-miR-191 and hsa-miR-200c following silencing of 
L1 expression. We also observed increased expression 
of a number of specific piRNAs, but overall, a decrease 
in total piRNA expression in the L1-silenced cells. The 
most highly up-regulated piRNAs were hsa_piR_000586, 
hsa_piR_001101 and hsa_piR_020450. Remarkably, these 
piRNA sequences showed a perfect match to C/D box 
snoRNAs residing in the introns of protein-coding genes, 
suggesting that expression of such piRNAs may influence 
gene expression. 
Considering the repeat-associated small RNAs that 
mapped to repetitive elements, in general we found no 
significant differences in the levels of the repeat RNAs 
in the presence or absence of L1 expression except for 
a few antisense RNAs potentially targeting subclasses of 
retrotransposons. The antisense repeat RNAs that were 
most differentially expressed between the L1-active and 
L1-silenced cells mapped to active L1 elements (L1M5, 
L1ME3), and the MIRc element. The majority of the 
repeat RNAs analyzed in this study are 18-23 nt in length 
suggesting that they are endogenous siRNAs as opposed 
to longer piRNAs, as would be expected in somatic cells. 
Since the mechanisms of biogenesis of small RNAs 
derived from repeat elements are not yet known, it is 
difficult to say whether these repeat RNAs are functional 
siRNAs, and answering this question would require a 
functional analysis. The alternative possibility is that 
leaky transcription from genomic repeats could produce a 
range of fragmented small RNA sequences, which may or 
may not be involved in the control of repetitive elements. 
It is also unclear why the genome expresses sense and 
antisense repeat RNAs against the oldest and inactive L2 
elements. It seems more likely that the L2-derived repeat 
RNAs are an exaptation of L2 sequences rather than a 
defense against them. Interestingly, our study shows that 
most of the repeat-associated small RNA reads mapped to 
the L1 family and only a small proportion mapped to SINE 
and LTR elements. The high proportion of repeat RNAs 
expressed against L1 elements is not unexpected as L1 
is the only known active retrotransposon in the genome.
The expression of L1 elements poses a substantial 
mutagenic threat to genomic stability. To control L1 
expression, cells have developed a variety of silencing 
mechanisms. Several types of small RNAs, including 
miRNAs, endo-siRNAs and piRNAs, have evolved as 
defense mechanisms against L1 activity. However, to date, 
there has been no report of bona fide human miRNAs that 
can target L1 elements. siRNAs can arise from dsRNA 
precursors, which are processed by the RNAi machinery 
to generate functional siRNAs against genomic repeats 
and retrotransposons [2, 4]. In connection with this, our 
recent study identified a number of L1-specific siRNAs 
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that can markedly silence endogenous L1 expression 
[20]. In addition, there are some cases of siRNAs and 
miRNAs originating from the same repetitive elements. 
For instance, many members of miR-548 family and 
siRNAs are derived from inverted-repeats of the MADE1 
retrotransposon [23].  piRNAs that repress L1 elements 
have been mainly found in germlines of a number of 
organisms but not in human somatic cells. Strikingly, 
recent reports of the presence of Piwi-class proteins 
suggest that active piRNAs might possibly exist in 
human cancer cells [38] and in this study we confirmed 
the presence of piRNAs in breast cancer cells. Notably, 
we found a number of differentially expressed piRNAs 
in L1-silenced cells that might potentially be involved in 
regulating cellular gene expression. 
Recent genome-wide studies have revealed that L1 
expression and retrotransposition occurs at a high level in 
the cancer genome, resulting in large-scale restructuring 
of the genome [14]. Consistent with this, widespread 
changes in gene expression have been found due to the 
expression of L1 elements in cancer cells [21]. Also, 
computational searches have identified a number of 
miRNAs and snoRNAs that are flanked by L1 sequences, 
suggesting that L1 activity could potentially influence the 
expression of small RNAs [25, 27]. However, it is not 
clear whether the structural and genetic changes caused by 
L1 retrotransposition might contribute to changes in small 
RNA expression or whether L1 elements might act as 
active promoters for small RNA expression. If this was the 
case, one would expect to observe a positive correlation 
between L1 expression and small RNA expression. On the 
contrary, we found that silencing of L1 expression induces 
the expression of a number of miRNAs. The differential 
expression of mature let-7 miRNAs in L1-active and 
L1-silenced cells is an intriguing finding; similar to 
the differential expression of let-7 seen in normal and 
cancer cells whereby the expression of let-7 is post-
transcriptionally inhibited in cancer cells [44]. Although 
at present, it is unclear if there is a functional relationship 
between the expression of let-7 and L1 elements, there 
is evidence indicating that cancer cells, which normally 
express high levels of L1 elements, have globally reduced 
levels of small RNAs, and in particular, miRNAs, 
compared to their normal counterparts [45].
At this stage, the underlying mechanism of the 
activation of the small RNAs in L1-silenced cells 
is unknown. One possibility is that silencing of L1 
expression substantially reduces the restructuring of the 
genome and the transcriptome that occurs in cancer. One 
could therefore argue that the relative expression of other 
RNAs should change in L1-silenced cells. Strikingly, it 
has been shown that inhibition of L1-encoded reverse 
transcriptase in several cancer cell types modulates 
cell growth and differentiation by affecting global gene 
expression [21]. Another recent study has proposed that 
the L1-encoded reverse transcriptase enzyme in cancer 
cells could actively be involved in reverse-transcription 
of small RNAs and mRNAs into cDNA resulting in the 
formation of RNA-DNA duplexes and thus impairing the 
formation of miRNAs and the expression of cellular genes 
[46]. Inhibiting the activity of RT by pharmacological 
inhibitors restores the normal profiles of small RNAs 
and subsequently affects  gene regulatory networks 
within the context of cellular growth. Another possibility 
is that DNA methylation and chromatin accessibility 
to RNA polymerase II has a role in the transcriptional 
activation or silencing of some of these small RNAs. A 
recent study in human cancer cells suggested that many 
genomic loci producing small RNAs are subjected to 
DNA hypermethylation, resulting in transcriptional 
repression of small RNA expression [47].  Defects in 
miRNA expression have also been attributed to the 
transcriptional repression of promoters [48]. Thus, as 
occurs with miRNAs, it is likely that other classes of 
small RNAs might also be subjected to DNA methylation-
associated repression. It would be interesting to further 
investigate possible changes in methylation patterns in the 
promoters of the identified small RNA loci, which might 
allow us to better understand the biological functions 
of differentially expressed small RNAs in the human 
genome. Nevertheless, the data presented in this study 
suggest that unanticipated interactions exist between the 
repression of L1 elements and the global expression of 
small RNAs. Although the exact regulatory pathways are 
unclear, this study proposes that, through direct silencing 
of L1 elements, the expression of small RNAs, including 
miRNAs and piRNAs, plays an important function in the 
maintenance of genomic integrity. 
METHODS
Cells, siRNAs and transfection. 
T47D (ATCC HTB-133) human breast cancer cells 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) with 2 mM L-glutamine and 10% FCS under 
standard cell culture conditions. An shRNA that mimicked 
22-nt of the L1-specific endo453 and a scrambled control 
shRNA were synthesized as described in reference [49] 
and cloned directly into a pSM2 vector (Open Biosystems) 
under the control of a U6 promoter. T47D cells were 
stably transfected with the scrambled control or L1-
specific shRNA constructs using an Amaxa nucleofector 
kit, followed by puromycin (0.5 µg/ml) selection for 10 
days. Depletion of L1 mRNAs was confirmed by qRT-
PCR as described previously [20].  Whole cell lysates 
were prepared by using MPER reagent (Pierce), following 
the manufacturer’s instructions. Western blot analysis 
was performed with anti-L1-ORF1p antibodies [15] at 1: 
2000 dilution, followed by addition of HRP-conjugated 
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secondary antibodies (Silenus, Australia). The resulting 
signals were visualized using the ECL chemiluminescence 
system (Pierce). To confirm protein normalization, the 
membranes were stripped and re-probed with α-tubulin 
antibodies (Sigma).
Small RNA library preparation and sequencing.  
Total RNA from control and endo453-transfected 
cells was extracted using TRIzol (Invitrogen). Low MW 
small RNA was enriched by adding 50% PEG-8000 
and 5M NaCl to a final concentration of 5% and 0.5M, 
respectively, followed by gel purification in a 15% urea-
PAGE gel (Invitrogen). Small RNAs ranging from 18-
30 nt were gel purified and ligated to 3’ adaptor and 5’ 
adaptor oligonucleotides as described in the Illumina 
Small RNA Kit. Briefly, the 3’-RNA adaptor (5’/5rApp/
ATCTCGTATGCCGTCTTCTGCTTG/3ddc/), which 
specifically ligates to RNAs that contain a hydroxyl 
group at their 3’end, was ligated to 1 µg of low MW 
small RNAs using T4 RNA ligase (NEB). The resulting 
products were subsequently ligated to the 5’-RNA adaptor 
(5’-GUUCAGAGUUCUACAGUCCGACGAUC-3’). 
cDNA was synthesized with SuperScript II Reverse 
Transcriptase (Invitrogen) and subjected to 12 cycles of 
PCR amplification with high-fidelity Phusion Polymerase 
(NEB) using primers as published by Illumina. Each 
library was loaded on a single Illumina lane at 20 pM and 
underwent 36 cycles of sequencing on an Illumina GAIIx 
Genome Analyzer.
Bioinformatic analysis of small RNAs. 
Singleton reads and reads with a 3’-adapter 
substring <6 nt or trimmed sequence length <17 nt were 
removed from the analysis carried out by the miRanalyzer 
pipeline. Trimmed reads were aligned to the miRBase 
database of human miRNAs (version 16) using Bowtie 
as implemented in the miRanalyzer pipeline (with the 
following Bowtie options: minimum score of 30 and 
minimum identity of 90%) [31]. Many miRNA sequences, 
especially those belonging to the same miRNA family, 
have a high degree of sequence similarity and since the 
read may be short (~ 16 bp), non-unique matches can 
occur. A non-unique match exists if a read maps with 
the same quality (i.e. same number of mismatches) 
to different positions or to more than one sequence in 
the library. Failure to report non-unique matches may 
represent loss of information. Therefore, miRanalyzer 
reports ambiguous matches, listing all miRNAs where 
matches have been found. The order of mapping against 
known miRNAs is firstly to mature, then mature-star and 
precursors/hairpin. Both unique matches (a read matching 
to a single known microRNA) and ambiguous matches 
are detected and removed from the input at each step. 
The sequential removal is important as otherwise the 
reads would be detected again in the precursor sequences 
(hairpins). For further details, refer to: http://bioinfo2.ugr.
es/miRanalyzer/miRanalyzer_tutorial.html#x1-110004.1.1 
In order to calculate differential expression, the mapped 
read counts were normalized and fold changes between 
L1-active and L1-silenced cells were calculated with the 
R/Bioconductor DESeq package [32] which is integrated 
into the miRanalyzer pipeline.
Detection and analysis of piRNAs and repeat-
associated RNAs.
To identify differentially expressed piRNAs, we 
selected the trimmed reads in each library with lengths 
greater than 23 nucleotides using the filter function in CLC 
Genomics Workbench 5.5.1 and mapped these subsets of 
reads against the human piRNABank database [30] using 
CLC Genomics Workbench with default parameters (i.e. 
maximum mismatches of 2 and strand-specific alignment). 
Each file of adapter-trimmed Illumina reads was aligned 
to the uncompressed Human.tar.gz piRNABank fasta  file 
after converting the fasta reads from RNA to DNA. The 
two files of mapped reads and read counts (for the L1-
active and L1-silenced libraries) were exported in plain 
text format from CLC Genomics Workbench and merged 
in R using the merge() command. The read counts were 
normalized using the DESeq package in R.
To identify differentially expressed RNAs mapping 
to repetitive elements, we selected the trimmed reads in 
each library with lengths less than 23 nucleotides using 
the filter function in CLC Genomics Workbench. Repeat 
RNAs were identified and annotated by alignment with 
the known rasRNA sequences in the deepBase database 
(version GRCh37)[31]. Alignments were carried out with 
CLC Genomics Workbench using default parameters (i.e. 
maximum mismatches of 2 and strand-specific alignment). 
Each subset of adapter-trimmed Illumina reads was 
aligned to the Human_sense_rasRNA_deepBase.fasta and 
Human_antisense_ rasRNA_deepBase.fasta files. The two 
files containing the mapped reads from the L1-active and 
L1-silenced libraries were exported from CLC Genomics 
Workbench and edited in MS Excel to remove extraneous 
text strings before importing and merging in R with the 
merge() command. The read counts were normalized 
using the DESeq package in R. The fasta headers of 
each sequence (containing the deepBase accession name, 
genomic coordinates and RepeatMasker name) from the 
human deepBase.fasta files were extracted and saved 
to a text file using the Linux grep command. The file 
containing the normalized reads from both libraries was 
merged with the file of fasta headers using the R merge() 
command. The RepeatMasker class and family for each 
RepeatMasker name were downloaded into a text file 
from the RepeatMasker [42] website with a Perl script 
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and further processed in MS Excel to remove extraneous 
columns and html tags before adding the RepeatMasker 
class and family names to the normalized reads file using 
the R merge() command. Read counts were accumulated 
for RepeatMasker classes and families using R. Additional 
details of the bioinformatics workflow and the Perl and R 
scripts are available on request.
SUPPLEMENTARY MATERIAL
Supporting information and supplementary tables 
are available online
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